A patient sat across from me last spring with an ultrasound report in her lap. Two intramural fibroids, the largest 4 cm. Heavy periods that had gotten worse over the past two years. Sleep falling apart. Brain fog she described as "underwater." She was 47, had been told by two prior providers that hormone therapy was off the table because of the fibroids, and arrived at the consultation half expecting me to say the same thing. I did not. The decision tree on fibroids and hormone therapy is more nuanced than the one-line "you can't" most patients get, and the consequences of getting it wrong — in either direction — are real.
This article walks through how I actually think about it.
What fibroids are doing physiologically — and why estrogen matters
Uterine fibroids — leiomyomas — are benign smooth-muscle tumors of the myometrium. They are extremely common: by age 50, somewhere between 70 and 80 percent of women have at least one, though most are asymptomatic. The ones that cause symptoms cause them through three mechanisms: mass effect (pressure on bladder, bowel, surrounding pelvic structures), abnormal bleeding (heavy or prolonged menstrual flow, intermenstrual spotting), and occasionally pain.
Fibroid biology is hormone-responsive. Both estrogen and progesterone receptors are expressed at higher density in fibroid tissue than in normal myometrium, and fibroids tend to grow during reproductive years and shrink after menopause when estrogen falls. This is the physiological observation that has driven decades of clinical hesitation about giving estrogen to a woman with fibroids — the assumption being that adding estrogen back will drive growth.
That assumption is partially correct and partially overstated. The clinical reality, drawn from a couple of decades of postmenopausal HRT data: most women with stable, asymptomatic, or mildly symptomatic fibroids tolerate physiologic-dose hormone therapy without significant fibroid growth. A subset do see growth, and a smaller subset see clinically meaningful growth. The decision tree is about identifying which group you are likely in before you start, then monitoring carefully once you do.
The decision tree I actually use
When I evaluate someone with known fibroids who is asking about hormone therapy, the questions I am working through, in order, are these:
Are you symptomatic from the fibroids right now? Heavy bleeding, anemia, mass-effect symptoms, pain. If yes, the fibroids need a management plan independent of the hormone question. Adding systemic estrogen on top of an actively symptomatic fibroid burden is not where I start.
Are you perimenopausal, postmenopausal, or surgically menopausal? This changes the math significantly. A perimenopausal woman with cycling estrogen does not need exogenous estrogen for fibroid-symptom reasons; she may need progesterone support, which often improves heavy bleeding rather than worsening it. A postmenopausal woman whose fibroids have been stable or shrinking for several years has a different risk profile than one fresh out of her last menstrual period.
What is the fibroid burden on imaging? Size, number, location. A single 2 cm subserosal fibroid carries different risk than five intramural fibroids totaling 10 cm of uterine volume. I want a recent pelvic ultrasound — within the past 12 months — before I write a plan.
What is the symptom picture driving the hormone-therapy question? Vasomotor symptoms, sleep disruption, mood and cognitive changes, libido loss, joint pain, vaginal atrophy. The intensity of those symptoms is the other side of the risk-benefit ledger. Severe quality-of-life impact justifies more aggressive intervention than mild symptoms do.
What labs do we have? Estradiol, progesterone, FSH, LH, total and free testosterone, SHBG, DHEA-S, full thyroid panel including reverse T3, fasting insulin, HbA1c, ferritin (especially with heavy bleeding), and a metabolic panel. Comprehensive lab work is the foundation of any real conversation here.
That set of inputs gives me a candidate map. Some patients are clearly good candidates for hormone optimization with appropriate fibroid surveillance. Some are clearly not, at least until the fibroid burden is addressed. Most are in the middle — meaning the conversation is about which delivery route, which dose, which adjuncts, and what the monitoring schedule looks like.
Why progesterone is the underrated piece
Most of the public conversation about fibroids and HRT focuses on estrogen. Progesterone gets less attention than it deserves. Progesterone receptors are heavily expressed in fibroid tissue too, and the relationship between progesterone and fibroid growth is more complex than the simple "progesterone protects" narrative.
What I actually see clinically: oral micronized progesterone at physiologic perimenopausal-replacement doses is generally well tolerated in women with fibroids, often improves the cyclical heavy bleeding that fibroids contribute to (because it stabilizes the endometrial lining), and is the appropriate progestogen choice when one is needed. Synthetic progestins are a different category and I do not use them in this practice.
Progesterone matters in another way too. In perimenopause, progesterone declines before estrogen does. The result is a state of relative estrogen dominance — not because estrogen is high in absolute terms, but because the unopposed estrogen-to-progesterone ratio is high. That is exactly the hormonal environment that fibroids respond to. Restoring physiologic progesterone is, paradoxically, often part of how you reduce the symptomatic burden of fibroids in this transition.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Delivery route changes everything
Oral estrogen has a first-pass hepatic effect that raises SHBG, raises clotting factors, and produces hormone exposures that are less physiologic than transdermal routes. For a woman with fibroids, transdermal delivery — patch, gel, or Biote pellet therapy — is generally my preference because the systemic exposure is steadier, lower in absolute peak, and avoids the first-pass hepatic effects that complicate the picture.
Pellets specifically deliver a steady-state dose over three to four months, which I find produces fewer fibroid-related symptom flares than methods with bigger peak-trough swings. They are not appropriate for every patient, and the candidacy conversation around pellets is its own discussion, but in the fibroid context the steady-state pharmacokinetics are an advantage.
How I monitor once we start
Starting hormone therapy in a woman with known fibroids is a commitment to surveillance. The protocol I use:
- Baseline pelvic ultrasound within the prior 12 months, or ordered before initiation if absent.
- Follow-up pelvic ultrasound at 6 months after initiation. This is not optional. I want imaging before the dose has been at full optimization for very long, so any meaningful growth is caught early.
- Ongoing surveillance ultrasound annually as long as the patient remains on therapy.
- Bleeding diary. Any new heavy bleeding, prolonged bleeding, or postmenopausal bleeding gets evaluated immediately, not at the next routine visit.
- Repeat labs at 3 months after initiation to confirm we are in the physiologic optimization range, not above it.
If imaging shows growth I am not comfortable with, the response is to dial dose down, change delivery route, or refer to gynecology for fibroid management before continuing. I do not white-knuckle a worsening picture.
When the right answer is not hormone therapy at all
Some patients arrive asking about hormone therapy when the actual right answer is fibroid treatment first. If your dominant complaint is heavy bleeding, anemia, or pelvic pressure from a large fibroid burden, hormone optimization is not going to fix that — and depending on what we add, it could make it worse. The right next step in those cases is a referral for fibroid management: discussion of options ranging from hormonal IUD for bleeding control, to uterine artery embolization, to myomectomy, to hysterectomy depending on burden, age, and your reproductive plans. Once the fibroid picture is stabilized, the hormone optimization conversation can resume.
I will tell you when that is the situation. I would rather refer you to the right specialist for the right intervention than treat outside the lane where I add value.
Adjacent factors that change the picture
Fibroids do not exist in isolation, and neither does the rest of your physiology. The factors I always look at alongside the fibroid question:
Iron status. Heavy menstrual bleeding from fibroids commonly produces iron deficiency anemia or — more often missed — iron deficiency without frank anemia. Ferritin under 50 ng/mL in this context is worth treating. Low iron is its own driver of fatigue, hair shedding, and exercise intolerance, and patients sometimes attribute all of those to "hormones" when iron is doing significant damage on its own.
Insulin and metabolic health. Insulin resistance promotes higher circulating estrogen and increases aromatase activity in adipose tissue — both of which feed fibroid biology. For patients whose lab picture includes elevated fasting insulin, addressing the metabolic side through a medical weight loss plan is part of the long-term fibroid strategy, not separate from it.
Thyroid. Subclinical hypothyroidism worsens menstrual bleeding patterns and overlaps symptomatically with perimenopause in ways that confuse the picture. Full thyroid panel, every time.
The clinical next step
If you have known fibroids and are weighing hormone therapy, the useful next move is a consultation with current imaging in hand. Bring the ultrasound report and the actual images on a CD or a portal printout if you have them. Bring a year's worth of menstrual cycle data — frequency, duration, pad count or "how often you change overnight" — even if it is approximate. Bring any hormone labs from the past 12 months. If you do not have any of that, do not delay the appointment to chase it; we order what we need at the visit.
I will walk you through the decision tree above using your specific picture, tell you which branch you are on, and recommend either a hormone optimization plan with the appropriate surveillance schedule or a fibroid-management referral first with hormone work to follow. You can book a consultation at the Columbus location or Warner Robins location. If you want a starting point before scheduling, the hormone health assessment takes about five minutes and helps clarify which questions to bring.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.